Published in J Mol Diagn on July 25, 2007
Mismatch repair protein expression and colorectal cancer in Hispanics from Puerto Rico. Fam Cancer (2010) 0.94
Application of molecular diagnostics for the detection of Lynch syndrome. Expert Rev Mol Diagn (2010) 0.89
Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency. Int J Clin Exp Med (2015) 0.83
Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients. Am J Surg Pathol (2016) 0.81
A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours. Fam Cancer (2012) 0.79
Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol (2014) 0.79
Lynch syndrome-related small intestinal adenocarcinomas. Oncotarget (2017) 0.75
PCR versus immunohistochemistry for microsatellite instability. J Mol Diagn (2008) 0.75
Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature (1993) 12.74
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med (2005) 9.39
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med (1998) 8.47
Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology (2000) 8.41
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol (2000) 3.98
It is time to get serious about diagnosing Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology (2005) 3.30
Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol (2005) 3.19
The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology (2001) 2.68
The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet (2001) 2.68
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res (2004) 2.37
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res (2002) 2.33
Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol (1999) 1.85
Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol (2005) 1.84
Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst (2007) 1.70
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer (2006) 1.68
Development of a fluorescent multiplex assay for detection of MSI-High tumors. Dis Markers (2004) 1.50
Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review. Am J Epidemiol (2002) 1.49
Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasms. Am J Surg Pathol (2005) 1.49
Hereditary nonpolyposis colorectal carcinoma (HNPCC) and HNPCC-like families: Problems in diagnosis, surveillance, and management. Cancer (2004) 1.39
Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining. J Pathol (2005) 1.35
Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining. Arch Pathol Lab Med (2003) 1.26
Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut (2002) 1.22
Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut (1999) 1.19
Correlation of mismatch repair genes immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology (2002) 1.16
What is the best way to assess microsatellite instability status in colorectal cancer? Study on a population base of 462 colorectal cancers. Am J Surg Pathol (2004) 1.10
Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors. Clin Cancer Res (2005) 1.00
Defective mismatch-repair colorectal cancer: clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. Am J Clin Pathol (2004) 0.96
Histopathology and mismatch repair status of 458 consecutive colorectal carcinomas. Am J Surg Pathol (2003) 0.93
Waiver of individual patient consent in research: when do potential benefits to the community outweigh private rights? Med J Aust (2007) 0.91
Routine detection of the replication error phenotype in clinical tumor specimens using fluorescence-SSCP. Biotechniques (2000) 0.88
Is it time to abandon microsatellite instability as a pre-screen for selecting families for mutation testing for mismatch repair genes? J Clin Oncol (2006) 0.86
Re: Ward et al. Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified. J Pathol 2005;207:377-384. J Pathol (2006) 0.84
Mismatch repair proteins and microsatellites hit clinical practice. Adv Anat Pathol (2000) 0.78
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol (2008) 6.01
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. Sci Transl Med (2012) 4.02
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol (2005) 3.48
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst (2013) 3.06
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology (2002) 2.85
Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst (2009) 2.56
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res (2003) 2.48
Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst (2012) 2.44
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol (2012) 2.22
Comparing survival outcomes for patients with colorectal cancer treated in public and private hospitals. Med J Aust (2007) 2.19
Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res (2006) 2.05
Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J Immunol (2009) 1.97
MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology (2005) 1.94
PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat (2005) 1.89
Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol (2012) 1.88
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
Fruit and vegetable consumption and the risk of proximal colon, distal colon, and rectal cancers in a case-control study in Western Australia. J Am Diet Assoc (2011) 1.68
BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer (2006) 1.68
Age-specific relationship between CD14 and atopy in a cohort assessed from age 8 to 25 years. Am J Respir Crit Care Med (2003) 1.64
The relationship between infant airway function, childhood airway responsiveness, and asthma. Am J Respir Crit Care Med (2004) 1.58
MicroRNA-130b regulates the tumour suppressor RUNX3 in gastric cancer. Eur J Cancer (2010) 1.57
Reduced infant lung function, active smoking, and wheeze in 18-year-old individuals. JAMA Pediatr (2013) 1.56
Dominantly inherited constitutional epigenetic silencing of MLH1 in a cancer-affected family is linked to a single nucleotide variant within the 5'UTR. Cancer Cell (2011) 1.56
Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat (2013) 1.55
Symptomatic viral infection is associated with impaired response to treatment in children with acute asthma. J Pediatr (2011) 1.50
Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity (2002) 1.49
DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett (2005) 1.48
Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res (2008) 1.48
Endoscopic ultrasound guided fine needle aspiration of solid pancreatic lesions: Performance and outcomes. J Gastroenterol Hepatol (2009) 1.45
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer. Cancer Biol Ther (2011) 1.45
Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. J Histochem Cytochem (2009) 1.38
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol (2004) 1.36
Risk factors for colorectal cancer in patients with multiple serrated polyps: a cross-sectional case series from genetics clinics. PLoS One (2010) 1.36
The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res (2003) 1.35
Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res (2010) 1.32
Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC Cancer (2010) 1.32
Methylation levels of LINE-1 repeats and CpG island loci are inversely related in normal colonic mucosa. Cancer Sci (2007) 1.31
IgE and IgG anti-house dust mite specificities in allergic disease. J Allergy Clin Immunol (2006) 1.29
CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol (2010) 1.29
Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PLoS One (2012) 1.28
Human rhinovirus species C infection in young children with acute wheeze is associated with increased acute respiratory hospital admissions. Am J Respir Crit Care Med (2013) 1.27
Phenotypic diversity in patients with multiple serrated polyps: a genetics clinic study. Int J Colorectal Dis (2010) 1.27
Novel FOXF1 mutations in sporadic and familial cases of alveolar capillary dysplasia with misaligned pulmonary veins imply a role for its DNA binding domain. Hum Mutat (2013) 1.23
Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clin Cancer Res (2006) 1.18
Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer (2009) 1.17
Detection of BRAF V600E mutation by pyrosequencing. Pathology (2008) 1.16
Prognostic significance of microsatellite instability and Ki-ras mutation type in stage II colorectal cancer. Oncology (2003) 1.16
Expression of sFRP-4 and beta-catenin in human colorectal carcinoma. Cancer Lett (2006) 1.15
APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. Int J Cancer (2006) 1.13
Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer (2006) 1.13
A case of 3q29 microdeletion with novel features and a review of cytogenetically visible terminal 3q deletions. Clin Dysmorphol (2006) 1.13
Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer (2009) 1.10
Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology (2012) 1.07
The MTHFR C677T and DeltaDNMT3B C-149T polymorphisms confer different risks for right- and left-sided colorectal cancer. Int J Cancer (2009) 1.07
Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis (2012) 1.06
Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol (2012) 1.01
Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score. AJR Am J Roentgenol (2007) 1.01
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep (2013) 1.01
Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. Am J Surg Pathol (2012) 1.00
Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK. J Biol Chem (2004) 1.00
Interleukin-10 (IL-10) polymorphisms are associated with IL-10 production and clinical malaria in young children. Infect Immun (2012) 0.99
Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases. Pathology (2005) 0.97
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. Int J Colorectal Dis (2007) 0.96
Target gene mutation profile differs between gastrointestinal and endometrial tumors with mismatch repair deficiency. Cancer Res (2002) 0.96
Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat (2004) 0.96
First-trimester combined screening for Down syndrome and other fetal anomalies. Obstet Gynecol (2006) 0.96
Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation. Int J Cancer (2013) 0.96
Childhood asthma and increased airway responsiveness: a relationship that begins in infancy. Am J Respir Crit Care Med (2008) 0.95
Evaluating genetic counseling: client expectations, psychological adjustment and satisfaction with service. J Genet Couns (2005) 0.94
Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin Gastroenterol Hepatol (2004) 0.93
Socio-demographic disparities in the uptake of prenatal screening and diagnosis in Western Australia. Aust N Z J Obstet Gynaecol (2010) 0.93
Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem (2006) 0.92
Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? Eur J Cancer (2013) 0.92
Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res (2003) 0.91
Waiver of individual patient consent in research: when do potential benefits to the community outweigh private rights? Med J Aust (2007) 0.91
Multiplicity and molecular heterogeneity of colorectal carcinomas in individuals with serrated polyposis. Am J Surg Pathol (2013) 0.91
Exome versus transcriptome sequencing in identifying coding region variants. Expert Rev Mol Diagn (2012) 0.90
The impact of single gene and chromosomal disorders on hospital admissions in an adult population. J Community Genet (2011) 0.89
Microsatellite instability in colorectal cancer. Asia Pac J Clin Oncol (2010) 0.89
Phenotyping: targeting genotype's rich cousin for diagnosis. J Paediatr Child Health (2014) 0.89